• Bio Roundup: Grail Acquisition, Libra's Launch, Tau Trial Results & More

    1 month ago - By Xconomy

    In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and stock deal. Grail set out with the goal of developing a diagnostic test that detects cancer from the genetic snippets tumors shed into the blood. The idea is to diagnose cancer well before symptoms show, giving clinicians a better chance to treat the disease. Grail has tested its technology in tens of thousands of patients and is now preparing to launch its first product next year...
    Read more ...